[et_pb_section fb_built=”1″ admin_label=”Hero section” _builder_version=”4.19.4″ _module_preset=”default” background_image=”https:\/\/tonetx.eu\/wp-content\/uploads\/2023\/02\/iStock-1189916097-scaled.jpg” background_position=”bottom_left” background_horizontal_offset=”-13%” background_vertical_offset=”46%” width=”100%” max_width=”100%” height=”368px” custom_margin=”|||” custom_padding=”10%||10%||false|false” global_colors_info=”{}”][et_pb_row column_structure=”2_3,1_3″ _builder_version=”4.16″ _module_preset=”default” custom_margin=”|||” global_colors_info=”{}”][et_pb_column type=”2_3″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”1px|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Lato||||||||” text_font_size=”20px” text_line_height=”1.8em” header_font=”Lato|900|||||||” header_font_size=”80px” header_letter_spacing=”2px” header_line_height=”1.2em” background_layout=”dark” animation_style=”fold” header_font_size_tablet=”46px” header_font_size_phone=”” header_font_size_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n
<\/p>\n
[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”100px|0px|100px|0px” global_colors_info=”{}”][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.19.4″ _module_preset=”default” background_color=”#ffffff” background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”||||false|false” custom_padding=”15px|15px|15px|15px|false|false” animation_style=”slide” animation_direction=”bottom” animation_intensity_slide=”6%” animation_starting_opacity=”100%” border_radii=”off|15px|15px||” border_color_all=”gcid-0881eb85-6db4-495d-84c3-350d3a9274f0″ border_width_top=”18px” box_shadow_style=”preset3″ box_shadow_vertical=”39px” box_shadow_blur=”80px” box_shadow_color=”rgba(0,0,0,0.1)” global_colors_info=”{%22gcid-0881eb85-6db4-495d-84c3-350d3a9274f0%22:%91%22border_color_all%22%93}”][et_pb_column type=”1_2″ _builder_version=”4.17.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/tonetx.eu\/wp-content\/uploads\/2022\/09\/Senza-titolo-1.png” title_text=”.” align=”center” _builder_version=”4.19.4″ _module_preset=”default” transform_translate=”-11px|46px” transform_origin=”52%|56%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.19.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.19.4″ _module_preset=”default” text_font=”Arial||||||||” text_text_color=”#1d1d1b” text_font_size=”15px” text_line_height=”2em” header_font=”||||||||” text_orientation=”center” custom_margin=”||||false|false” global_colors_info=”{}” header_2_font=”Josefin Sans|700|||||||” header_2_text_color=”#b5bf0e” header_2_font_size=”42px” header_2_line_height=”1.5em” max_width=”1128px” module_alignment=”center” hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
T-One Therapeutics\u2019 goal is to develop more effective therapies to fight cancer and autoimmune diseases.<\/p>\n
The break-through novelty resides in the identification of LINE1-transcripts as the first of a new class of immune response inhibitors that regulate T cells exhaustion by controlling their gene expression profiles. These results could revolutionize current immunotherapies with novel RNA-based therapies aimed at awakening T lymphocytes effector response at transcriptional level.<\/strong><\/p>\n With our experimental approach we aim to produce new drugs for immunotherapy, through the exploitation of antisense oligonucleotides (ASOs), in order to achieve higher patients response rate and also to reduce side effects that have been reported so far, thus improving patients quality of life.<\/p>\n [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”Hero section” _builder_version=”4.19.4″ _module_preset=”default” background_image=”https:\/\/tonetx.eu\/wp-content\/uploads\/2023\/02\/iStock-1189916097-scaled.jpg” custom_margin=”|||” custom_padding=”10%||10%|” locked=”off” global_colors_info=”{}”][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" RESEARCH T-One Therapeutics\u2019 goal is to develop more effective therapies to fight cancer and autoimmune diseases. The break-through novelty resides in the identification of LINE1-transcripts as the first of a new class of immune response inhibitors that regulate T cells exhaustion by controlling their gene expression profiles. These results could revolutionize current immunotherapies with novel […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-314","page","type-page","status-publish","hentry"],"yoast_head":"\n